Next Phase Newsletter

A venture capital and private equity firm invests in breakthrough industrial technologies and, within the life sciences, is looking to invest in companies developing R&D and manufacturing tools and services. The firm is interested in companies that have at least some data through a pilot or a pharma partner to validate their technology. The firm invests primarily in North America-based companies, but will consider international companies that have significant operations in the US.

The firm invests in tools and services for R&D and manufacturing within the life sciences. This can include diagnostics platforms, AI/ML based drug discovery platforms, analytics or manufacturing tools. The firm invests primarily in technologies that do not require FDA approval, and looks for companies with some data validation of their technology with an external partner.

The firm prefers to lead and take a board seat when investing, but will occasionally co-invest as well. The firm will also consider follow-on investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office based in East Coast USA looks to invest in medical devices and diagnostics, but will also consider therapeutics and digital health. The firm prefers company that have some proof of concept data, with some animal studies complete, and will invest through to clinical-stage companies. The firm generally co-invests in a syndicate, and will invest between $100-500K, depending on the stage of development of the company. The firm is currently interested in investing in companies located in North America.

The firm is focused primarily on medical devices and diagnostics, but will consider therapeutics, if they are first in class, and digital health, with a focus on AI-related technologies. The firm has focused on technologies related to oncology, diabetes and kidney diseases, but will consider other indications as well.

The firm is interested in companies with strong management teams. As the firm will generally co-invest, board representation is not usually required after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private equity firm based in headquartered in Japan has a typical investment size of USD 3-5 million per company. The firm’s geographical focus is Asia, but may consider companies in the US and Europe. The firm is actively seeking new investment opportunities.

In the life sciences, the firm will primarily focus on therapeutics, and is also interested in medical devices and digital medicine.  The firm is interested in new technologies such as cell and gene therapies, but also considers investing in small molecules and biologics, as well as biosimilars and reformulated drugs. The firm will invest in any indication area, and invests in companies from the late preclinical stage through to Phase II.

The firm is usually a follow-on investor.  For early stage opportunities, the firm prefers that the company has a clinical trial plan in place.  While the firm is interested in international opportunities, they prefer that the company is interested in expanding into Japan or Taiwan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm headquartered in the USA, had its beginnings as an incubator, providing seed funding to very early-stage companies for the first two years. Since then, the firm has also branched into a venture arm that expanded the investment focus to Series A financing rounds. The firm is actively seeking investments and will allocate around $500K – 2.5 M, with preferred financing structures being equity and convertible preferred equity. Although the firm has invested in companies outside the USA, the firm focuses its investments on USA-based companies.

In the life sciences space, the firm is primarily interested in healthcare IT/digital health technologies and services as well as medical devices and diagnostic tools that have a tech-enabled component. The firm is open to devices of all FDA regulatory pathways including 510k and PMA. Products that have not begun clinical trials will most likely be considered too early, so these devices should at least be undergoing clinical trials. The firm is not interested in companies in the therapeutics sector.

The firm seeks to work with privately owned companies with an experienced management team that is dedicated full-time. CEOs with experience founding successful start-up companies is a strong plus. The firm can act as either a lead or co-investor in financing rounds, and will generally seek a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Western Europe is investing from its most recent fund closed in 2016. The firm makes equity investments in life sciences and biomedical technology companies at all stages of development. However, the firm prefers late stage preclinical or early stage clinical for therapeutics and diagnostics and medical devices that are close to market approval. The typical investment per round is €4M to €10M. The firm looks for companies that are based in the US, Canada, Israel, and Europe. The firm is actively screening new investment opportunities.

The firm is generally opportunistic in the life sciences space. The firm targets therapeutics and diagnostics, medical devices, and biopharmaceuticals. In therapeutics, the firm focuses on drug development and is open to all indications including orphan indications. In medical devices, the firm has a special focus on interventional devices in cardiology, gastroenterology and pulmonology that are close to or on the market approval. However, the firm is equally opportunistic in other subsectors and indications for medical devices, but all with a therapeutic focus.

The firm invests in companies at all stages of their development. For drug development, the firm invests from late preclinical to mid-stage clinical development. The firm sometimes considers companies with products on the market. The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early-stage venture capital firm based in Taiwan was formed by a group of successful entrepreneurs. The firm specializes in incubation, seed and early venture investments in technology-heavy sectors. The firm is currently investing from its latest fund that closed in 2016. Typical equity allocations range from $500K to $3M in seed to series A rounds. The firms open to either leading a financing round or joining a syndication. The firm is currently seeking opportunities from USA and Taiwan.

Within life sciences, the firm considers medical devices, IVD tools, digital health and healthcare internet of things (IoT). Within medtech, the firm is looking for early stage projects with solid unmet medical need. On-market products are less of interest. The firm is open to all risk levels and all disease indications. The firm is also interested in material science and agricultural biotech.

The firm is an active investor. The firm can work with incomplete teams, assist companies with regulatory strategy and product definition, and help overseas businesses find manufacturing partners in Taiwan. The firm typically takes a board seat in a portfolio company for projects they led.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A China-based healthcare fund focuses on global growth opportunities. The company is based in Shanghai with additional offices in USA and China. In 2015, the firm launched a VC fund focused on Seed to Series A opportunities in healthcare. Typical early-stage investment through this early-stage fund is US$5-10M. The firm prefers to lead in a financing round but is also open to co-investing. The firm is currently seeking opportunities from the US, China, Europe and Israel.

When it comes to early-stage healthcare investments, the firm is extremely opportunistic across sectors. The firm’s focus is divided between 80 percent pharma and biotech, reserving 20 percent for devices, healthcare IT and services. In terms of disease areas, The firm prefers technologies targeting large unmet medical need and is less interested in rare diseases. The firm is seeking opportunities in Seed or Series A stage. In the Diagnostics space, C-Bridge only looks for products in the commercial stage from China.

The firm is looking for experienced teams with strong sector expertise. As a China-based fund, the firm seeks to add value in the Chinese market through joint venture, registration expertise, and distribution channels.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.